Enjoy complimentary customisation on priority with our Enterprise License!
The global human combination vaccines market size is estimated to grow by USD 7.03 billion at a CAGR of 8.69% between 2023 and 2028. The market has experienced significant growth, driven by the surge in infectious diseases, increasing newborn population, and government-backed initiatives for vaccine programs. These vaccines address various diseases, including polio, Haemophilus influenzae, and Hepatitis B. By combining multiple vaccines into one, the number of injections needed is reduced, thereby enhancing the overall immunity system. Leading market players, such as GSK, Merck and Co., and Sanofi, control over 70%-75% of the market share. These companies' dominance is attributed to their robust research and development capabilities, extensive distribution networks, and proven track records in producing effective and safe vaccines.
To learn more about this report, Download Report Sample
The inactivated vaccine segment segment is estimated to witness significant growth during the forecast period. The inactivation technique provides greater coverage against various diseases. They are developed using pathogen particles that have been destroyed or killed and, therefore, cannot divide. Inactivated are safer than live vaccines because they cannot imitate a vaccinated individual, resulting in no risk of return to a virulent form capable of causing diseases. The inactivation technique allows the incorporation of viral and bacterial strains into the vaccine.
Get a glance at the market contribution of various segments Download PDF Sample
The inactivated vaccines segment was valued at USD 8.88 billion in 2018 and it will continue to grow during the forecast period. The human combination inactivated vaccines can be subjected to freeze-drying and, therefore, is easy to store. They can be transported in large quantities across the globe. Considering the numerous advantages, the human combination inactivated vaccines will witness a high adoption rate during the forecast period, thus driving the market growth. Governments globally are continuously increasing awareness. For instance, the United Nations Children Fund (UNICEF), a United Nations agency, and the World Health Organization (WHO) are supporting countries in their efforts to reimagine immunization by restoring services by adhering to hygiene and physical distancing recommendations and providing protective equipment to health workers. Therefore, such initiatives positively impacted the market in 2020 and are expected to continue accelerating growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and analysis, and drivers will shape the market during the forecast period. The continuous efforts by vendors and national organizations to promote the use of will drive the growth of the market in North America during the forecast period. Additionally, the regional market is witnessing an increasing number of initiatives to generate awareness about immunization programs and increase people's access, which will also drive market growth during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Abbott Laboratories: The company offers human combination vaccines such as Enteroshield, Influvac vaccine 2014, Influvac Jr vaccine, Rotasure, and Pentashield.
Abbott Laboratories, Arabio, Bharat Biotech., Zydus Lifesciences Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., Walvax Biotechnology Co. Ltd., and Biological E. Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Human combination vaccines refer to medical preparations containing two or more antigens designed to elicit an immune response against multiple diseases. Side effects, although rare, may occur after vaccination. Medical practitioners advise monitoring for potential adverse reactions. Logistic constraints and regulatory policies pose challenges in the distribution and administration of these vaccines. The threat of bioterrorism has increased the demand for combination vaccines, such as MMR (Measles, Mumps, and Rubella), Chickenpox, DTaP (Diphtheria, Tetanus, and Pertussis), IPV (Inactivated Poliovirus), Pediarix, Pentacel, Tetraxim, and MMRV (Measles, Mumps, Rubella, and Varicella). These vaccines contain inactivated virus strains or antigens that stimulate the immune system to fight infections. Government efforts and vaccination programs have contributed to the reduction of coronavirus infected cases and death rates. The ongoing pandemic has highlighted the importance of vaccines in preventing the spread of diseases caused by various organisms. The market for human combination vaccines continues to grow due to the increasing need for effective and efficient health solutions. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
The rise in cases of infectious diseases is notably driving the market growth. Infectious diseases are a prevalent cause of sickness and death across the world. The market continues to gain significance in the healthcare industry, as medical practitioners turn to these vaccines to mitigate the risks of various infectious diseases. However, the use is not without challenges. Side effects, logistic constraints, and regulatory policies pose obstacles to their widespread adoption. For instance, the side effects of some combination vaccines, such as Pediarix and Pentacel, may include fever, irritability, and pain at the injection site. Logistical constraints, such as the need for refrigerated storage and complex administration procedures, can make it challenging to deliver these vaccines to remote areas. Regulatory policies also play a crucial role in shaping the market. For example, the approval process for new combination vaccines can be lengthy and costly. Bioterrorism is another factor driving the demand, as these vaccines can provide protection against multiple diseases and organisms with a single vaccine shot.
Further, the market includes major players such as Sanofi Pasteur, which produces vaccines against diseases like chickenpox, DTaP, IPV, and influenza. Other vaccine producers, such as Tetraxim, offer vaccines against diseases like hepatitis A and B, meningococcal disease, and HPV. The immune system's ability to respond effectively to antigens from inactivated virus strains is crucial in the development of effective Human Combination Vaccines. The demand for vaccination against infectious diseases, including coronavirus infected cases and their associated high death rates, has led to increased government efforts and vaccination programs. The HIV vaccine remains a significant area of research and development in the field of Human Vaccines, particularly in pediatrics. However, the challenge of antiviral drug resistance continues to pose a threat to the effectiveness of vaccines and the overall health of patients. In conclusion, the market offers significant opportunities for growth, but also presents challenges related to side effects, logistical constraints, and regulatory policies. The ability to provide protection against multiple diseases with a single vaccine shot and the ongoing research and development in the field of Human Vaccines make this an exciting area to watch. To address this challenge, the CDC is striving to reduce the incidence of these diseases by ensuring broad immunization coverage and providing access to recommended vaccines for low-income children and adults.
Threat from bioterrorism is a major cause of concern which is a primary trend shaping market growth. Human Combination Vaccines have gained significant importance in the medical field due to their ability to protect against multiple diseases using a single vaccine shot. These vaccines contain antigens derived from various organisms, including bacteria, viruses, and fungi, which stimulate the immune system to produce an immune response against multiple diseases. The production of Human Combination Vaccines has become crucial due to the emergence of new diseases and the potential threat of bioterrorism. However, the use is not without challenges. Medical practitioners must consider potential side effects, logistic constraints, and regulatory policies when administering these vaccines. Side effects may include fever, soreness at the injection site, and allergic reactions.
Logistic constraints, such as storage and transportation requirements, can make it challenging to distribute these vaccines effectively. Regulatory policies also play a significant role in production and distribution, as they must undergo rigorous testing and approval processes. Despite these challenges, the demand is on the rise due to the increasing number of infectious diseases and the potential threat of bioterrorism. For instance, vaccines such as the Chickenpox vaccine, DTaP vaccine, IPV vaccine, Pediarix vaccine, Pentacel vaccine, Tetraxim vaccine, and others have proven effective in preventing various diseases. Vaccine producers, such as Sanofi Pasteur, are investing heavily in research and development to create new and improved Human Combination Vaccines. Government efforts and vaccination programs have also played a significant role in increasing the demand for Human Combination Vaccines. For example, the coronavirus pandemic has highlighted the importance of vaccines in preventing the spread of infectious diseases and saving lives. According to recent data, coronavirus infected cases have reached millions, and death rates continue to rise.
As a result, governments and healthcare organizations are investing in immunization campaigns to increase vaccination rates and protect their populations. In conclusion, it plays a vital role in protecting against multiple diseases using a single vaccine shot. However, medical practitioners must consider potential side effects, logistic constraints, and regulatory policies when administering these vaccines. Despite these challenges, the demand is on the rise due to the increasing number of infectious diseases and the potential threat of bioterrorism. Vaccine producers are investing heavily in research and development to create new and improved Human Combination Vaccines, and government efforts and vaccination programs are increasing vaccination rates to protect populations. As a result, research against potential bioterrorism agents is increasing, which is expected to boost the market growth and trends in the forecast period.
The incompatibility of vaccine components can restrain market growth. A combination vaccine is made up of various antigens that provide immunity against different diseases. While some combinations can boost the immune response of one or more components, not all vaccine components are compatible with each other. Incompatibility can lead to vaccine instability or a suboptimal immune response.
For example, combining DTaP and IPV in infants reduced the immune response to the P antigen and decreased antibody production for different antigens after two doses, and toward pertussis toxin after three doses. This resulted in a suboptimal response compared to administering these two separately. To overcome compatibility issues, extensive research with advanced biotechnological tools is necessary to modify combination vaccine immunogenicity. Such incompatibility issues may hinder the growth of the global market in the forecast period.
The market research report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market is expanding due to innovations in computational and systems biology, bioinformatics, and machine learning. These advancements support the development of vaccines such as the chicken pox vaccine, which uses an inactivated virus strain to combat infection. In the pediatric population, essential vaccines include the D and T vaccine, acellular pertussis, Haemophilus influenza Type B with lyophilized Hib vial, and the MMRV vaccine.
Moreover, the rise of the novel coronavirus has intensified the demand for COVID-19 vaccines and prompted efforts like the Vaccine Equity Initiative. Key vaccine types such as conjugate vaccines, recombinant vaccines, and attenuated vaccines play a crucial role in disease prevention. Side effects like headache and fatigue are common but manageable. Additionally, the MMR vaccine and other biological agents enhance immune responses and improve metabolism in children.
Market Scope |
|
Report Coverage |
Details |
Page number |
176 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.69% |
Market Growth 2024-2028 |
USD 7.03 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.81 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key countries |
US, UK, Canada, Germany, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Arabio, Bharat Biotech., Zydus Lifesciences Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., Walvax Biotechnology Co. Ltd., and Biological E. Ltd. |
Market dynamics |
Parent market growth analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period. |
Customization purview |
If our market analysis and report have not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.